NCT05559853 Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
| NCT ID | NCT05559853 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Brain Metastases |
| Study Type | OBSERVATIONAL |
| Enrollment | 119 participants |
| Start Date | 2022-09-22 |
| Primary Completion | 2027-09-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 119 participants in total. It began in 2022-09-22 with a primary completion date of 2027-09-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).
Eligibility Criteria
Inclusion Criteria: Healthy volunteers \[for Study Aim 1 (SA1) and Study Aim 2 (SA2)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * No known cancer diagnosis Patients \[for Study Aim 1 (SA1)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) Patients \[for Study Aim 3 (SA3)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) * Planned SRS treatment Exclusion Criteria: Healthy volunteers (SA1 \& SA2) and patients (SA1 \& SA3) exclusion criteria: * Pregnant or breastfeeding women * Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest * Age \< 18 years
Contact & Investigator
Ouri Cohen, PhD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT05559853 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Metastases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05559853 currently recruiting?
Yes, NCT05559853 is actively recruiting participants. Contact the research team at coheno1@mskcc.org for enrollment information.
Where is the NCT05559853 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05559853 clinical trial?
NCT05559853 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Ouri Cohen, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 119 participants.